EUVIMEDEUVIMED entdecken
Multizentrische StudieLeitlinieOpen Access · CC BY-NC 4.0

Pharmaco-Disparities in Heart Failure: A Survey of the Affordability of Guideline Recommended Therapy in 10 Countries

Tauben Averbuch iD, Meisam Esfahani, Rani Khatib, James Kayima, Juan Jaime Miranda, Rishi K Wadhera, Faiez Zannad, Ambarish Pandey, Harriette G C Van Spall

ESC Heart Failure · 2023

DOI: 10.1002/ehf2.14468 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift ESC Heart Failure, 2023. Verfasst von Tauben Averbuch und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, McMaster University, Hamilton, Ontario, Canada. Hauptthemen laut MEDLINE: Heart Failure. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Heart failure with reduced ejection fraction (HFrEF) is treatable but guideline-directed medical therapy (GDMT) may not be affordable or accessible to people living with the disease. Methods and results In this cross-sectional survey, we investigated the price, affordability, and accessibility of four pivotal classes of HFrEF GDMT: angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB) or angiotensin-neprilysin inhibitors (ARNI); beta-blockers; mineralocorticoid receptor antagonists (MRA); and sodium glucose co-transporter 2 inhibitors (SGLT2i). We sampled online or community pharmacies in 10 countries across a range of World Bank income groups, assessing mean 30 day retail prescription prices, affordability relative to gross national income per capita per month, and accessibility. We reported median price ratios relative to the International Reference Standard. We performed a literature review to evaluate accessibility to GDMT classes through publicly funded drug programmes in each country. HFrEF GDMT prices, both absolute and relative to the international reference, were highest in the United States and lowest in Pakistan and Bangladesh. The most expensive drug was the ARNI, sacubitril/valsartan, with a mean (standard deviation, SD) 30 day price ranging from $11.06 (0.81) in Pakistan to $611.50 (3.54) in United States. The least expensive drug was the MRA, spironolactone, with a mean (SD) 30 day price ranging from $0.18 (0.00) in Pakistan to $12.32 (0.00) in England. Affordability (SD) of quadruple therapy—ARNI, beta-blockers, MRA, and SGLT2i—was best in high-income and worst in low-income countries, ranging from 1.49 (0.00)% of gross national income per capita per month in England to 232.47 (31.47)% in Uganda. Publicly funded drug programmes offset costs for eligible patients, but ARNI and SGLT2i were inaccessible through these programmes in low- and middle-income countries. Price, affordability, and access were substantially improved in all countries by substituting ARNI for ACEi/ARB.

Conclusions

There was marked variation between countries in the retail price of HFrEF GDMT. Despite higher prices in high-income countries, GDMT was more accessible and affordable than in low- and middle-income countries. Publicly funded drug programmes in lower income countries increased affordability but limited access to newer HFrEF GDMT classes. Pharmaco-disparities must be addressed to improve HFrEF outcomes globally.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureHumansCross-Sectional StudiesPractice Guidelines as TopicGlobal HealthSurveys and QuestionnairesHealth Services AccessibilityAngiotensin Receptor Antagonists

Stichwörter der Autor:innen

AccessibilityAffordabilityCostEquityHeart failurePharmaco-disparitiesPharmacotherapy

Substanzen

Angiotensin Receptor Antagonists

Autor:innen und Institutionen

  • Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
  • Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.
  • Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
  • Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
  • Department of Cardiology, Uganda Heart Institute, Kampala, Uganda.

ORCID-Profile: Tauben Averbuch

Zitieren

APA

Averbuch, T., Esfahani, M., Khatib, R., Kayima, J., Miranda, J. J., Wadhera, R. K., Zannad, F., Pandey, A., & Van Spall, H. G. C. (2023). Pharmaco-Disparities in Heart Failure: A Survey of the Affordability of Guideline Recommended Therapy in 10 Countries. ESC Heart Failure. https://doi.org/10.1002/ehf2.14468

Vancouver

Averbuch T, Esfahani M, Khatib R, Kayima J, Miranda JJ, Wadhera RK, et al. Pharmaco-Disparities in Heart Failure: A Survey of the Affordability of Guideline Recommended Therapy in 10 Countries. ESC Heart Failure. 2023. doi:10.1002/ehf2.14468

BibTeX
@article{Averbuch2023,
  author = {Averbuch, Tauben and Esfahani, Meisam and Khatib, Rani and Kayima, James and Miranda, Juan Jaime and Wadhera, Rishi K and Zannad, Faiez and Pandey, Ambarish and Van Spall, Harriette G C},
  title = {Pharmaco-Disparities in Heart Failure: A Survey of the Affordability of Guideline Recommended Therapy in 10 Countries},
  journal = {ESC Heart Failure},
  year = {2023},
  doi = {10.1002/ehf2.14468}
}
Kostenlos starten →